Pacira BioSciences, Inc. (PCRX)
Working capital turnover
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Revenue | US$ in thousands | 700,966 | 674,978 | 666,823 | 541,533 | 420,830 |
Total current assets | US$ in thousands | 745,130 | 509,994 | 498,334 | 866,048 | 651,623 |
Total current liabilities | US$ in thousands | 309,920 | 97,383 | 147,774 | 521,118 | 253,328 |
Working capital turnover | 1.61 | 1.64 | 1.90 | 1.57 | 1.06 |
December 31, 2024 calculation
Working capital turnover = Revenue ÷ (Total current assets – Total current liabilities)
= $700,966K ÷ ($745,130K – $309,920K)
= 1.61
The working capital turnover ratio for Pacira BioSciences, Inc. has shown a generally increasing trend over the past five years, from 1.06 in December 31, 2020, to 1.61 in December 31, 2024. This indicates that the company's efficiency in utilizing its working capital to generate sales has improved over the period. The peak value of 1.90 at December 31, 2022 suggests a significant enhancement in the company's ability to convert its working capital into revenue during that year. Overall, the rising trend in the working capital turnover ratio reflects positively on Pacira BioSciences' management of working capital resources to support its business operations.
Peer comparison
Dec 31, 2024